A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Clamp, A.R., Blackhall, F., Vasey, P., Soukop, M., Coleman, R., Halbert, G., Robson, L. and Jayson, G.C. (2003) A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. British Journal of Cancer, 89, pp. 1152-1154. (doi:10.1038/sj.bjc.6601285)

Full text not currently available from Enlighten.

Abstract

Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:UNSPECIFIED
Authors: Clamp, A.R., Blackhall, F., Vasey, P., Soukop, M., Coleman, R., Halbert, G., Robson, L., and Jayson, G.C.
College/School:College of Medical Veterinary and Life Sciences
Journal Name:British Journal of Cancer

University Staff: Request a correction | Enlighten Editors: Update this record